HOVON 181

A study investigating the effect of adding bleximenib to standard treatment with intensive chemotherapy in patients with a specific form of acute myeloid leukemia (AML)

Coordinating Investigator

  • Alexandre Theocharides

    Alexandre Theocharides

    President, Project Group Leukemia

The treatment of adult patients with acute myeloid leukemia (AML) must be further improved. The current standard of care consists of chemotherapy and, if indicated, a stem cell transplant from a donor. However, the disease remains incurable for a significant number of patients. Bleximenib is a new drug that blocks the interaction between a protein called menin and other proteins in leukemia cells. When this interaction is disrupted by bleximenib, the leukemia cells are killed.

The primary objective is to assess whether treatment with bleximenib, when administered in addition to standard therapy, improves treatment outcomes in adult patients with newly diagnosed AML and mutations in the NPM1 or KMT2A genes.

This is a randomized, double-blind, placebo-controlled Phase III clinical trial.

The study will enroll 875 previously untreated patients with AML who have a specific alteration in the DNA of their leukemia cells (a KMT2A rearrangement or an NPM1 mutation).

Participants will be assigned to one of three treatment groups:

  • Group 1: Standard treatment plus bleximenib and maintenance treatment with bleximenib
  • Group 2: Standard treatment plus bleximenib and maintenance treatment with a placebo
  • Group 3: Standard treatment plus a placebo and maintenance treatment with a placebo

After completion of treatment in accordance with the study protocol, a 4-year follow-up period will begin from the date of enrollment of the last patient for the purpose of monitoring. The results of the various treatment groups will be compared.

Intervention Studied

Depending on the randomization result, participants will receive standard intravenous chemotherapy with (Treatment Group 1) or without bleximenib (Treatment Group 3), and the outcomes of these patient groups will be compared. Depending on the risk assessment, standard treatment may also include a stem cell transplant from a donor. In this study, a maintenance treatment period is added to the initial treatment plan. During maintenance therapy, patients will receive either bleximenib or a placebo. This is done to gain insight into the potential benefits of prolonged use of bleximenib (comparison of outcomes in treatment groups 1 and 2).

During the study, most (diagnostic) tests are part of standard care. However, during maintenance therapy, a maximum of 8 additional bone marrow tests will be performed. When standard bone marrow tests are performed, additional bone marrow will be collected for the study. Additional blood is also collected when blood is drawn as part of the standard procedure anyway.

Inclusion Criteria

  • 18 years of age or older with newly diagnosed AML with a mutation in NPM1 or KMT2A and deemed eligible for intensive chemotherapy
  • WHO/ECOG performance status ≤ 2
  • Adequate renal and hepatic function prior to randomization

Exclusion Criteria

  • Previous (chemotherapy) treatment for AML
  • Known active leukemic involvement of the central nervous system
  • Heart disease or chronic respiratory disease requiring supplemental oxygen

Hospitals

  • HFR Freiburg - Kantonsspital
    HFR Freiburg - Kantonsspital
  • HOCH Health Ostschweiz - Kantonsspital St. Gallen
    HOCH Health Ostschweiz - Kantonsspital St. Gallen
  • Inselspital - Universitätsspital Bern
    Inselspital - Universitätsspital Bern
  • Kantonsspital Aarau AG
    Kantonsspital Aarau AG
  • Les hôpitaux universitaires de Genève
    Les hôpitaux universitaires de Genève
  • Universitätsspital Basel
    Universitätsspital Basel
  • USZ Universitätsspital Zürich
    USZ Universitätsspital Zürich

Further Studies: Leukemia

Recruitment completed

CLL 17

A prospective, randomized, unblinded, multicenter, phase III study comparing the efficacy and safety of ibrutinib monotherapy versus time-limited therapy with venetoclax plus obinutuzumab or ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) - CLL17

Recruitment completed

HOVON 150

A multicenter, double-blind, randomized, placebo-controlled phase 3 study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with blast excess-2, with an IDH1 or IDH2 mutation, respectively, who are eligible for intensive chemotherapy.

Recruitment completed

HOVON 155

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.

Recruitment completed

HOVON 156

A phase 3, multicenter, open-label, randomized, study of Gilteritinib versus Midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

HOVON 173

Ivosidenib and azacitidine with or without venetoclax in adult patients with newly diagnosed IDH1-mMutated AML or MDS/AML considered ineligible for intensive chemotherapy

HOVON 177

A study to investigate the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not been previously treated and are not eligible for intensive chemotherapy

GRAALL 2024

A randomized study involving 3 cohorts to evaluate the role of new immunotherapies and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first-line treatment of adult patients with acute lymphoblastic leukemia